Brenzavvy (bexagliflozin)
Type 2 Diabetes
ApprovedActive
Key Facts
About TheracosBio
TheracosBio is a commercial-stage biotech company commercializing Brenzavvy, an SGLT2 inhibitor for type 2 diabetes, with a distinct business model based on affordable pricing to drive rapid market penetration. The company leverages an experienced leadership team with deep expertise in regulatory affairs, clinical development, and supply chain management. Its strategy involves forging partnerships with pharmacies and distributors to ensure low-cost access, positioning it uniquely in the competitive diabetes market. TheracosBio aims to address healthcare disparities by making newer therapeutics accessible to a broader patient population immediately upon approval.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| Metformin API | USV Biologics Division | Commercial |
| Empagliflozin | Azico Biophore | Commercial |
| Sitagliptin Intermediate | AR Life Science | Commercial |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Sitagliptin Phosphate Polymorph | Morepen Laboratories | Pre‑clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |